{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:49Z","timestamp":1793817589895,"version":"4.6.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,7,14]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Idelalisib as upfront therapy for CLL caused an early hepatotoxicity in a subset of primarily younger patients with IGHV-mutated disease. Multiple lines of evidence suggest that this adverse effect is immune mediated, perhaps through inhibition of regulatory T cells.<\/jats:p>","DOI":"10.1182\/blood-2016-03-707133","type":"journal-article","created":{"date-parts":[[2016,5,31]],"date-time":"2016-05-31T20:45:35Z","timestamp":1464727535000},"page":"195-203","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":268,"title":["Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity"],"prefix":"10.1182","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6033-3363","authenticated-orcid":false,"given":"Benjamin L.","family":"Lampson","sequence":"first","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddha N.","family":"Kasar","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago R.","family":"Matos","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-9337","authenticated-orcid":false,"given":"Elizabeth A.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women's Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rassenti","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA;"},{"name":"CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Davids","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S.","family":"Freedman","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Arnason","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Beth Israel Deaconess Medical Center, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA;"},{"name":"CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5441-1516","authenticated-orcid":false,"given":"Joshua","family":"Fein","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hanna","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-6849","authenticated-orcid":false,"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"},{"name":"CLL Research Consortium, Moores UCSD Cancer Center, La Jolla, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2019111902270099700_B1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.330.330","article-title":"Second interim analysis of a phase 3 study of idelalisib (ZYDELIG\u00ae) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): Efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract].","volume":"124","author":"Sharman","year":"2014","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111902270099700_B2","first-page":"1","article-title":"Update on a phase 1 study of the selective PI3K-delta inhibitor, idelalisib (GS-1101) in combination with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia.","volume":"98","author":"Coutre","year":"2013","journal-title":"Haematologica"},{"issue":"21","key":"2019111902270099700_B3","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.2878.2878","article-title":"A phase 1 study of the selective PI3K\u03b4 inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia [abstract].","volume":"122","author":"De Vos","year":"2013","journal-title":"Blood"},{"key":"2019111902270099700_B4","author":"Coutre"},{"key":"2019111902270099700_B5","author":"Zelenetz"},{"issue":"25","key":"2019111902270099700_B6","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia.","volume":"126","author":"O\u2019Brien","year":"2015","journal-title":"Blood"},{"issue":"5583","key":"2019111902270099700_B7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"issue":"12","key":"2019111902270099700_B8","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000525","article-title":"Idelalisib-associated enterocolitis: Clinicopathologic features and distinction from other enterocolitides.","volume":"39","author":"Louie","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2019111902270099700_B9","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients.","volume":"39","author":"Weidner","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"2019111902270099700_B10","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion.","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111902270099700_B11","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111902270099700_B12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa040857","article-title":"ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.","volume":"351","author":"Rassenti","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111902270099700_B13","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2007-05-092882","article-title":"Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.","volume":"112","author":"Rassenti","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111902270099700_B14","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.0902875","article-title":"Analyses of recombinant stereotypic IGHV3-21-encoded antibodies expressed in chronic lymphocytic leukemia.","volume":"186","author":"Ghia","year":"2011","journal-title":"J Immunol"},{"issue":"8","key":"2019111902270099700_B15","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood-2004-03-0818","article-title":"Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.","volume":"104","author":"Widhopf","year":"2004","journal-title":"Blood"},{"key":"2019111902270099700_B16","first-page":"3","article-title":"Immunogenetics sequence annotation: The strategy of IMGT based on IMGT-ONTOLOGY.","volume":"116","author":"Giudicelli","year":"2005","journal-title":"Stud Health Technol Inform"},{"issue":"Database issue","key":"2019111902270099700_B17","doi-asserted-by":"crossref","first-page":"D593","DOI":"10.1093\/nar\/gki065","article-title":"IMGT, the international ImMunoGeneTics information system.","volume":"33","author":"Lefranc","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2019111902270099700_B18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2559.2008.03069.x","article-title":"Patterns of liver infiltration in lymphoproliferative disease.","volume":"53","author":"Baumhoer","year":"2008","journal-title":"Histopathology"},{"issue":"10","key":"2019111902270099700_B19","doi-asserted-by":"crossref","first-page":"6598","DOI":"10.4049\/jimmunol.177.10.6598","article-title":"Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells.","volume":"177","author":"Patton","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"2019111902270099700_B20","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1208\/aapsj080106","article-title":"Mechanisms of drug-induced liver injury.","volume":"8","author":"Holt","year":"2006","journal-title":"AAPS J"},{"issue":"10","key":"2019111902270099700_B21","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1002\/eji.200425071","article-title":"CCL3\/MIP-1alpha is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4(+) T cells to the liver.","volume":"34","author":"Ajuebor","year":"2004","journal-title":"Eur J Immunol"},{"issue":"1","key":"2019111902270099700_B22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1172\/JCI6642","article-title":"Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease.","volume":"104","author":"Murai","year":"1999","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111902270099700_B23","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.4049\/jimmunol.1001156","article-title":"CCR6 marks regulatory T cells as a colon-tropic, IL-10-producing phenotype.","volume":"185","author":"Kitamura","year":"2010","journal-title":"J Immunol"},{"issue":"11","key":"2019111902270099700_B24","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood-2009-07-232330","article-title":"PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.","volume":"115","author":"Soond","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111902270099700_B25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation.","volume":"196","author":"Clayton","year":"2002","journal-title":"J Exp Med"},{"issue":"7505","key":"2019111902270099700_B26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer.","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"issue":"5","key":"2019111902270099700_B27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri3650","article-title":"FOXP3 and scurfy: how it all began.","volume":"14","author":"Ramsdell","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"2019111902270099700_B28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaci.2007.08.044","article-title":"Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells.","volume":"120","author":"Torgerson","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"22","key":"2019111902270099700_B29","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia.","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111902270099700_B30","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1182\/blood.V92.4.1165","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.","volume":"92","author":"Keating","year":"1998","journal-title":"Blood"},{"issue":"8","key":"2019111902270099700_B31","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcph.495","article-title":"Clinical drug interaction profile of idelalisib in healthy subjects.","volume":"55","author":"Jin","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"2019111902270099700_B32","first-page":"e307","article-title":"B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.","volume":"100","author":"Zaborsky","year":"2015","journal-title":"Haematologica"},{"issue":"10","key":"2019111902270099700_B33","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.leu.2403907","article-title":"Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia.","volume":"19","author":"Motta","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"2019111902270099700_B34","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/cncr.25752","article-title":"Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.","volume":"117","author":"Weiss","year":"2011","journal-title":"Cancer"},{"issue":"suppl 1","key":"2019111902270099700_B35","first-page":"1","article-title":"TGR-1202, A novel once daily PI3K-delta inhibitor, demonstrates clinical activity with A favorable safety profile, lacking hepatotoxicity, in patients with CLL and B-cell lymphoma.","volume":"100","author":"Burris","year":"2015","journal-title":"Haematologica"},{"issue":"23","key":"2019111902270099700_B36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2942.2942","article-title":"A phase I trial of TGR-1202, a next generation once daily PI3K-delta inhibitor in combination with obinutuzumab plus chlorambucil, in patients with chronic lymphocytic leukemia [abstract].","volume":"126","author":"Mahadevan","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2019111902270099700_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4158.4158","article-title":"Preliminary results of a phase ib study of duvelisib in combination with FCR (dFCR) in previously untreated, younger patients with CLL [abstract].","volume":"126","author":"Davids","year":"2015","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/2\/195\/1397296\/195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/128\/2\/195\/1397296\/195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T18:21:20Z","timestamp":1656613280000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/128\/2\/195\/35469\/Idelalisib-given-frontline-for-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-03-707133","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726392645.793538188","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]}}}